Cadrenal Therapeutics Stock (NASDAQ:CVKD)
Previous Close
$12.96
52W Range
$5.40 - $32.55
50D Avg
$14.62
200D Avg
$9.56
Market Cap
$24.86M
Avg Vol (3M)
$65.85K
Beta
-
Div Yield
-
CVKD Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| IKT | Inhibikase Therapeutics, Inc. |
| XCUR | Exicure, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| HCWB | HCW Biologics Inc. |
| GPCR | Structure Therapeutics Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| NVCT | Nuvectis Pharma, Inc. |